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Abstract
Background: Tuberous sclerosis (TSC) related tumors are characterized by constitutively activated mTOR signaling due to
mutations in TSC1 or TSC2.
Methods: We completed a phase 2 multicenter trial to evaluate the efficacy and tolerability of the mTOR inhibitor, sirolimus,
for the treatment of kidney angiomyolipomas.
Results: 36 adults with TSC or TSC/LAM were enrolled and started on daily sirolimus. The overall response rate was 44.4%
(95% confidence intervals [CI] 28 to 61); 16/36 had a partial response. The remainder had stable disease (47.2%, 17/36), or
were unevaluable (8.3%, 3/36). The mean decrease in kidney tumor size (sum of the longest diameters [sum LD]) was 29.9%
(95% CI, 22 to 37; n=28 at week 52). Drug related grade 1–2 toxicities that occurred with a frequency of .20% included:
stomatitis, hypertriglyceridemia, hypercholesterolemia, bone marrow suppression (anemia, mild neutropenia, leucopenia),
proteinuria, and joint pain. There were three drug related grade 3 events: lymphopenia, headache, weight gain. Kidney
angiomyolipomas regrew when sirolimus was discontinued but responses tended to persist if treatment was continued
after week 52. We observed regression of brain tumors (SEGAs) in 7/11 cases (26% mean decrease in diameter), regression of
liver angiomyolipomas in 4/5 cases (32.1% mean decrease in longest diameter), subjective improvement in facial
angiofibromas in 57%, and stable lung function in women with TSC/LAM (n=15). A correlative biomarker study showed that
serum VEGF-D levels are elevated at baseline, decrease with sirolimus treatment, and correlate with kidney angiomyolipoma
size (Spearman correlation coefficient 0.54, p=0.001, at baseline).
Conclusions: Sirolimus treatment for 52 weeks induced regression of kidney angiomyolipomas, SEGAs, and liver
angiomyolipomas. Serum VEGF-D may be a useful biomarker for monitoring kidney angiomyolipoma size. Future studies are
needed to determine benefits and risks of longer duration treatment in adults and children with TSC.
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Tuberous sclerosis (TSC) is a tumor suppressor gene disorder
characterized by the development of benign tumors (hamartomas)
in multiple organs [1]. It is an autosomal dominant disorder with
high penetrance but variable expression, and the majority (60–
70%) of newly diagnosed individuals have a spontaneous
mutation. There are approximately 50,000 individuals living with
TSC in the U.S. and approximately 1 million worldwide. The
diagnosis is based on a series of major and minor clinical criteria
[2]. The disease causing genes (TSC1 and TSC2) have been
identified and the ‘‘two-hit’’ mechanism of disease has been
demonstrated in many tumors [3], but haploinsufficiency may
explain some aspects of brain involvement [4,5]. TSC patients can
have a number of medical problems including epilepsy, cognitive
impairment, behavioral disorders, brain lesions (tubers, subepen-
dymal nodules and subependymal giant cell astrocytomas), kidney
angiomyolipomas, kidney cysts, early onset kidney cancer, skin
tumors (facial angiofibromas), cardiac tumors (rhabdomyomas)
and pulmonary abnormalities including lymphangioleiomyomato-
sis (LAM) [6,7,8].
Hamartin and tuberin, the TSC1 and TSC2 gene products, form
a complex that inhibits mammalian target of rapamycin (mTOR)
in a conserved cellular signaling pathway (PI3kinase- Akt-mTOR
pathway) that regulates nutrient uptake, growth and protein
translation [9,10,11]. Rapamycin (also known as sirolimus,
RapamuneH) is an mTOR kinase inhibitor that is an approved
drug for immunosuppression following kidney transplantation, and
rapamycin analogs have recently been approved for the treatment
of kidney cancer and pancreatic neuroendocrine tumors
[12,13,14]. Rapamycin normalizes dysregulated mTOR signaling
in cells that lack normal hamartin or tuberin. Furthermore, there
is now substantial evidence that inhibiting mTOR kinase in
preclinical rodent models of TSC may be useful for treating
tumors and brain manifestations of TSC [5,15,16,17,18]. It is
important to note that tumors and brain tissue from rodent models
for TSC have similar abnormalities in mTOR signaling (with
hyperphosphorylated S6 kinase and ribosomal subunit S6) as brain
tumors (subependymal giant cell astrocytomas) [19], kidney
tumors (angiomyolipomas) from TSC patients [20], and abnormal
lung tissue from LAM patients [21].
Kidney angiomyolipomas are a common and problematic
major clinical feature of TSC. These tumors consist of blood
vessels, smooth muscle, and fat cells. They occur in approximately
75% of TSC patients over the age of 6–8 years [6,22], and are a
significant cause of morbidity and mortality [23]. Growth of
kidney angiomyolipomas associated with TSC is common and has
been reported in 47% of TSC patients in a cohort of 60 children
(ages 1–18) [22], and in 91% in a cohort of 32 TSC patients (ages
,1 year to 36 years) [24]. Kidney angiomyolipomas can also cause
pain, bleeding, and varying degrees of renal failure. The current
standard of care is to monitor kidney angiomyolipomas with
imaging every 1–3 years. If there is evidence of rapid tumor
growth, tumor size .4 cm, or symptoms, surgical removal or
vascular embolization is recommended. In a recent review of 102
patients with kidney angiomyolipomas followed for a median of 4
years, 25 required intervention [25]. In that series, vascular
embolization was the most common intervention recommended,
but was often problematic as 6 of 19 (31.5%) patients had
complications (post embolization syndrome-3, abscess-1, nonfunc-
tioning kidney-1, refractory hypertension-1). Development of
effective medical therapy for these tumors could allow some
patients to avoid the risks of one or more invasive procedures.
We implemented this multicenter sirolimus trial to provide
efficacy and safety data regarding the treatment of TSC associated
angiomyolipomas with sirolimus. In addition to the primary
endpoints evaluating safety and kidney angiomyolipoma response,
we investigated the utility of mTOR inhibitor treatment for many
common clinical features of TSC by collecting secondary endpoint
data on liver angiomyolipomas, subependymal giant cell astrocy-
tomas (SEGAs), tubers, subependymal nodules (SENs), seizures,
skin lesions (facial angiofibromas, hypomelanotic macules, sha-
green patches, forehead plaques), renal cysts, kidney function, and
lung function in those individuals with LAM. We also collected
data on TSC gene mutations and explored the utility of serum
vascular endothelial growth factor D (VEGF-D) as a biomarker for
TSC associated kidney angiomyolipomas.
Methods
Enrollment and study design
Participants were recruited at 6 clinical sites in the U.S. Five of
the clinical sites were comprehensive TSC clinics (Boston,
Cincinnati, Loma Linda, Hartford, New York) and one was a
Urology clinic (Dallas). The protocol was approved by the
appropriate institutional review boards (IRBs) which included: 1)
Dana-Farber Cancer Institute IRB; 2) UT Southwestern Medical
Center IRB; 3) Connecticut Children’s Medical Center IRB; 4)
Cincinnati Children’s Medical Center IRB; 5) NYU School of
Medicine IRB; 6) Loma Linda University IRB. The study was
registered with clinicaltrials.gov (ID NCT00126672) and conduct-
ed according to institutional and national guidelines. This was an
open label, single arm, multicenter study with a Simon two-stage
design [26]. Initially 13 patients were enrolled; an additional 23
patients were enrolled after the first partial response was observed
in the initial cohort. After written informed consent was obtained,
participants were registered, baseline testing was completed, and
oral treatment with sirolimus was started. A copy of the original
protocol is included in the online supporting information files
(Protocol S1).
Eligibility and Exclusion Criteria
Eligible patients were 18–65 years old with at least one kidney
angiomyolipoma $2 cm in diameter and a diagnosis of TSC or
LAM. Additional inclusion criteria included adequate renal, liver,
and bone marrow function (Cr,4.1, SGOT, SGPT, TBili, Alk
Phos all,26normal, hematocrit .30, normal WBC, and platelets
.100,000). Patients were excluded if they had unstable seizures
(recent changes in seizure pattern or use of anti-epileptic agents),
clinically significant bleeding from kidney angiomyolipoma(s),
severe LAM (dependent on continuous supplemental oxygen or
limited performance status), evidence for accelerating renal
dysfunction or acute renal failure, renal cell carcinoma (suspected
or known), active infection, recent use of other investigational
agent in the 30 days prior to study entry, or prior history of
coronary artery disease. Pregnant or nursing women were also
excluded.
Objectives
The primary objectives were the evaluation of kidney
angiomyolipoma response and tolerability of sirolimus. The
overall response rate was determined using magnetic resonance
imaging (MRI) before and after treatment according to the
Response Evaluation Criteria in Solid Tumors (RECIST) [27].
According to RECIST, kidney angiomyolipoma size is defined as
the sum of the longest diameters (sum LD) of up to five target
lesions per kidney (in cm); a partial response is $30% decrease in
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complete response is complete tumor regression; all other changes
are considered stable disease. The percent change in sum LD was
calculated using this formula: ((sum LD time 2 - sum LD time 1)/
sum LD time 1)*100. NCI Common Toxicity Criteria, version 3.0,
were used to assess toxicity. Secondary objectives included
evaluation of other TSC lesions (SEGAs, liver angiomyolipomas,
tubers, SENs, kidney cysts, skin lesions) before and after 52 weeks
of sirolimus treatment, pulmonary function testing, renal function
testing, and collection of samples for correlative biomarker
analyses. Exploratory objectives included longer term follow up
(at 18 months and 24 months) in two subgroups (ON
SIROLIMUS AFTER WK 52 and OFF SIROLIMUS AFTER
WK 52), and investigation of serum VEGF-D as a biomarker.
Sirolimus dosing and drug levels
Sirolimus treatment was initiated with a loading dose of 6 mg by
mouth on day 1 followed by 2 mg by mouth daily. Sirolimus is
FDA approved for use after kidney transplantation and this is the
standard dose used in the kidney transplant population. The dose
was then adjusted to maintain a target blood level of 3–9 ng/ml
for the first 16 weeks. After week 16, the dose of sirolimus was
increased to a target level of 9–15 ng/ml unless there was evidence
for a partial response or complete response by kidney MRI. There
was no change in dose for those with a partial response or
complete response at week 16. Trough sirolimus levels were
checked every 8–12 weeks (at 24 weeks, 32 weeks, 40 weeks, and
52 weeks) in all patients until the 12-month (week 52) study visit. If
the sirolimus dose was below target, the dose was increased by 1–
2 mg until the target trough level was achieved. Sirolimus levels
were checked every 2–3 weeks while the dose was adjusted.
There was a wide range of sirolimus doses required to maintain
target trough levels. At the end of year 1 (week 52), the mean daily
dose was 6.7 mg per day. The lowest dose was 1 mg every other
day and the highest dose was 24 mg per day. Sirolimus is
metabolized by CYP3A4 and at the dose extremes, subjects were
taking concomitant drugs that likely had a significant impact on
drug metabolism. The participant on the lowest dose was also on
verapamil, a CYP3A4 inhibitor, which should reduce the
clearance of sirolimus. The participant on the highest dose was
on primidone, a CYP3A4 inducer, which should increase the
clearance of sirolimus. During our study there were 5 participants
that exceeded the upper limit of our target levels (15 ng/ml) at any
time. Almost all participants (28/33, 85%) required a one time
dose increase per protocol at week 16 because they did not have a
partial response.
We had a low threshold to hold sirolimus doses during minor
infections or to allow symptomatic mouth ulcers to heal, so
many participants had drug held at some point during the
course of the study. Per our protocol, if there were more than 10
consecutive missed doses, these were made up at the end of year
1 on study so that 28 participants received ,52 weeks of
sirolimus treatment (range 49–56 weeks). We monitored
sirolimus levels every 8–12 weeks in order to avoid toxicity by
holding or reducing doses if the target drug level was exceeded.
There is substantial evidence indicating a single steady state
trough sirolimus level corresponds well to drug exposure because
it has been well documented that the 24 hour trough sirolimus
level correlates well with the AUC (area under concentration
time curve) [28,29]. Drug level monitoring allowed relatively
rapid dose adjustments to maintain target levels and was also
useful for verifying that participants were taking sirolimus as
directed throughout the study.
VEGF-D assay
Serum was collected using standard clinical red top serum
collection vacutainer tubes with no additive. After clot formation,
the tube was spun at low speed, the serum was collected, aliquoted,
frozen, and shipped overnight on dry ice to the Dabora Lab at
Brigham and Women’s Hospital, Boston, MA. VEGF-D levels
were measured using ELISA (Quantikine Human VEGF-D
Immunoassay kit from R&D Systems, catalog number DVED00).
The VEGF-D ELISA was done according the manufacturer’s
protocol (Quantikine Human VEGF-D Immunoassay kit from
R&D Systems) with the following modifications: 1) known
concentrations of 125, 250, 500, 1000, 2000, 4000, and
40,000 pg/ml were used to generate the standard curve; 2) we
used a correction wavelength of 550 nm instead of 540 nm
because 540 nm was not an option on our plate reader
(THERMOmax microplate reader, Molecular Devices Corp.); 3)
sample concentrations were extrapolated from the standard curve
using GraphPad Prism software (version 4.01) using the one-site
competition option in order to optimize the fit of the standard
curve [30]. All standards were run in quadruplicate (all readings
were within 25% of the mean of all 4 readings). All clinical samples
were run in duplicate and duplicates deviated by no more than
25% from the average of the two readings. As there was some
plate to plate variability in VEGF-D assay results for identical
samples, the baseline (week 0) and week 52 samples from each
subject reported here were run on the same plate so concentrations
for both time points were determined from the same standard
curve.
Statistical considerations, sample size, and statistical
analysis
Since this trial was designed in 2003 (before there was any
published clinical data available on the efficacy of mTOR
inhibitors for TSC related tumors), a two-stage adaptive design
was employed because it would allow early stopping if there was
no evidence for response in a small cohort of subjects, but
continuation if there was some early evidence of efficacy [26]. Our
protocol was designed to enroll an initial cohort 13 eligible
subjects; if there were no responses observed among the first 13
eligible subjects, the study would have been discontinued and the
regimen declared unpromising. However, if one response was
observed among the first 13 subjects, then enrollment would
continue and an additional 22 eligible patients would be included.
The sample size was determined based on the following: if 4 or
more responses are observed among 35 total eligible patients, the
regimen will be considered worthy of further study. Alternatively,
if 3 or fewer responses are observed, the regimen will be declared
unpromising. According to power calculations, a study with this
design had a 51% probability of stopping early if the true response
rate was 5%, 8.4% probability of declaring the treatment effective
at the end of the study if the response rate was 5%, and 90%
probability of declaring the treatment effective if the response rate
was 20%. Note: we enrolled 36 subjects (with IRB approval)
because the final two subjects were recruited at approximately the
same time.
GraphPad Prism software (version 4.01) was used for all data
analysis, with a p-value#0.05 indicating statistical significance. A
paired t test or Wilcoxon signed rank test (for non-parametric data)
was used for paired quantitative variables. An unpaired t test or
Mann-Whitney test (for non-parametric data) was used for
unpaired quantitative variables. A two-sided Fisher’s exact test
was used for categorical variables. Spearman correlation was used
to investigate the correlation between kidney angiomyolipoma size
and VEGF-D levels.
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There were a total of 64 protocol deviations/violations that
were reported to the Dana-Farber IRB between March 2007 and
August 2009. Deviations/violations occurred in these categories:
baseline testing issue-2, baseline testing timing issue-2, consent
issue-6, documentation-1, eligibility issue-7, eligibility issue and
baseline testing timing-2, enrollment target issue-2, lab test
missing-2, lab test timing-7, missing data-1, study conduct issue-
3, study drug dispensing issue-1, study drug issue-1, treatment
issue-10, visit date issue-13, visit date and leaving study early-3,
visit date and missing data-1. These deviations/violations were
judged to have minimal impact on risks to the subjects and did not
affect overall data quality. Many of the violations/deviations
prompted amendments to allow clinically and scientifically
acceptable changes that would reduce the number of future
deviations/violations. All deviations/violations were submitted to
the IRB for review, and our corrective action plan was approved
in all cases. We have included the complete list of deviations/
violations with the description as reported to the Dana-Farber IRB
(Table S13).
During the course of this study we submitted a total of 3
amendments that modified the study design (Amendments 15, 17,
and 20). Amendment 15 was submitted in August 2007 and
approved in February 2008. It included the following changes in
eligibility requirements: the platelet count requirement was
changed to .100,000 (from normal), the white blood count
(WBC) requirement was changed to absolute neutrophil count
(ANC) .1500 (from WBC normal), eligible age was changed to 3–
65 years (from 16–65 years), exclusion of those with kidney bleed
was changed to exclusion of those with clinically significant kidney
bleed; baseline renal function required was changed to eGFR of at
least 30 (from creatinine less than 4.1 ). There were also minor
changes made in timing of tests or timing of visits including these:
baseline kidney MRI should be done within 4 weeks (instead of 2
weeks); sirolimus levels should be done within 2 weeks of target
date. A change was also made to allow CT scanning instead of
MRI for patients unable to undergo MRI testing. A number of
other minor changes were made to improve or clarify study details.
Amendment 17 was submitted in February 2008 and approved in
March 2008. The change requested was to increase target
enrollment from 36 to 76 participants. However, we were unable
to obtain adequate funding to increase the enrollment so unable to
implement this change in enrollment. Amendment 20 was
submitted in January 2009 and approved in June 2009. This
change was requested to allow additional sirolimus treatment
during months 12–24 if the treating site investigator judged that
this was in the best interest of the study participant. Additional
details regarding this amendment can be found in the results
section. The final protocol version and CONSORT checklist are
included in the supporting information (Protocol S2, Checklist S1).
Results
Enrollment and Baseline Characteristics
We enrolled 36 adults between December 2005 and April 2008.
All participants met diagnostic criteria for TSC [2] and 21 subjects
also had clinical evidence for LAM (19 women and 2 men).
Baseline characteristics are shown in Table 1. See Table S8 for
details of TSC gene mutation testing.
Regression of kidney tumors during the first 52 weeks
After baseline testing was completed, participants were started
on oral sirolimus at a dose of 6 mg on day 1, then 2 mg per day.
The sirolimus trough level was measured 1–3 weeks later and the
dose was adjusted to an initial target range of 3–9 ng/ml. Kidney
angiomyolipoma size was evaluated by MRI at baseline and weeks
16, 32, and 52 during year 1 (CT was used for 1 subject who was
unable to undergo MRI). In those patients with a partial response
at week 16, drug treatment continued at the same dose. The
sirolimus dose was increased for all other patients to achieve a
trough target range of 9–15 ng/ml. Sirolimus treatment continued
for 52 weeks. Tolerability and drug levels were monitored every 8–
12 weeks.
There were 36 adults enrolled and 28 were evaluable at 12 and
24 months (see Figure 1). There were 8 participants who were
removed from the study early. This included 4 who were unable to
keep follow-up study appointments, and 4 who were taken off
study because of a serious adverse event that was judged unrelated
to drug therapy (1-hospitalized with complicated infectious
mononucleosis, 1-diagnosed with a pancreatic neuroendocrine
tumor, 1-hospitalized with a kidney angiomyolipoma hemorrhage,
1-hospitalized with a neurologic event). All of these patients
recovered from these events. All subjects were included in the
safety analysis. All but 3 had at least one kidney MRI scan so were
evaluable for response of kidney angiomyolipomas to sirolimus
treatment.
According to RECIST criteria [27], the overall response rate
was 16/36 (44.4%, 95% CI, 28 to 61); all were partial responses.
There were 17/36 (47.2%) with stable disease and 3/36 (8.3%)
were not evaluable because they were removed from study prior to
a follow-up MRI. There were none with progressive disease or a
complete response. In those individuals who completed 52 weeks
of treatment, there were 15/28 with a partial response (53.6%
response rate, 95% CI, 35 to 72%) and 13/28 (46.4%) with stable
disease. The mean (6 standard deviation) number of kidney
angiomyolipomas per patient was 3.862.2. Most participants
(69%) had at least 1 kidney angiomyolipoma $4 cm, and 19%
had at least 1 kidney angiomyolipoma $10 cm. The mean (6
standard deviation) kidney angiomyolipoma size (sum LD) at
baseline was 21.2 cm614.6, and after 52 weeks, decreased to
14.5611.3 cm. The mean percent decrease in kidney tumor sum
LD at week 52 was 29.9% (95% CI, 22–37%, n=28), see Figure 2.
In the 28 that completed 52 weeks of treatment, the majority had
their best response at week 52 (13), but in some cases the best
response was at week 16 (4) or week 32 (6). The best response was
at 24 months in 5 cases (see next section). There were 33 with
evaluable disease, but 28 that completed all 52 weeks of treatment.
The subject with progressive disease during sirolimus treatment at
weeks 16 and 32 had a single small tumor that increased in size
from 2.2 cm (baseline) to 3.2 cm (week 16, 45% increase in sum
LD). Details regarding timing of response, numbers of tumors, and
kidney tumor size are shown in Table S1. In a post-hoc
comparison of response rates at different clinical sites, we did
note that one site had a better response rate than the others. This
type of comparison was not part of our study design and the
numbers are small so we are unable draw any firm conclusions
except to suggest that future multicenter TSC trials should
evaluate differences across sites so that potential biases can be
investigated. MRI images of kidney angiomyolipoma regression
are shown in Figures S1, S2, S3 .
Changes in kidney tumor size during months 12–24
Assessing kidney tumor size during months 12–24 was another
objective. In the original version of our protocol, this was a
secondary objective and the plan was to stop sirolimus at week 52
and evaluate kidney tumor size at 18 and 24 months in all subjects.
However, tumor regrowth after stopping sirolimus treatment was
observed in a similar single institution study [31] that was
Multicenter Sirolimus Trial for Tuberous Sclerosis
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Characteristic
Number
(range) % Characteristic
Number
(range) %
Ave. age at study enrollment, years 34 (19–60) BRAIN
Ave. age when TSC diagnosed, years 13 (0–60) Subependymal nodules (SENs)* present 30 83%
Diagnosis Subependymal nodules (average number) 3.4 (0–8)
TSC 13 36% Cortical Tubers* 30 83%
TSC & LAM* 23 64% None 4 11%
Sex Minimal (0–2) 3 8%
Male 10 28% Mild (3–5) 3 8%
Female 26 72% Moderate (6–10) 11 31%
Race Severe (11+)1 3 3 6 %
White 34 94% Unknown 2 6%
Black 1 3% Subependymal Giant Cell Astrocytoma* 13 36%
Other 1 3% Seizures
ECOG performance status 0 32 89% chronic 7 19%
ECOG performance status 1 4 11% prior history 20 56%
never 8 22%
RENAL unknown 1 3%
Kidney angiomyolipomas* Cognitive impairment 15 42%
Average sum of the longest diameters (sum LD), cm 21.2 (2.0–51.8) None 21 58%
Average number of measurable kidney
tumors per person
3.8 (1–10) Mild 10 28%
Angiomyolipoma diameter .4 cm 25 69% Moderate 4 11%
Angiomyolipoma diameter .10 cm 7 19% Severe 1 3%
Prior invasive kidney procedures 18 50% Psychological/Behavioral Issues 18 50%
Nephrectomy 7 19% ADHD 1 3%
Biopsy 3 8% Anxiety 5 14%
Vascular emobolization 6 17% Autism 1 3%
More than one 2 6% Depression 2 6%
Kidney Cysts** 22 61% More than one 9 25%
None 14 39% None 18 50%
0–2 Small Cysts (,2 cm) 5 14%
.2 Small Cysts (,2 cm) 6 17% OTHER
.2 Cysts with at least one .2 cm 9 25% History of cardiac rhabdomyoma* 4 11%
Classic Polycystic Disease 2 6% Liver angiomyolipoma 15 42%
Chronic renal insufficiency (Cr$1.5 mg/dl) 6 17% Retinal hamartoma* 10 28%
Proteinuria 4 11% Genetics
Hematuria 4 11% TSC2 mutation 14 39%
TSC1 mutation 0 0%
SKIN No mutation identified 4 11%
Facial angiofibromas* 35 97% Mutation unknown (not tested or test
inconclusive)
18 50%
None 1 3%
Macular lesions only on cheek 3 8%
Papular lesions, ,3 mm diameter 22 61%
Papular lesions, .3 mm diameter 10 28%
Hypomelanotic macules* 24 67%
Shagreen patch* 22 61%
Ungual/subungual fibromas* 20 56%
Forehead plaque* 14 39%
*TSC major feature.
**TSC minor feature.
doi:10.1371/journal.pone.0023379.t001
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protocol to allow additional sirolimus treatment during months
12–24. This additional sirolimus treatment was offered to those
individuals who had a partial response or stable disease if the
treating study physician felt it was in the best interest of the
participant. There were 14 patients who were eligible for sirolimus
treatment during year 2 because the others had completed (or
almost completed) all 24 months by the time the amendment was
approved. Of these patients, additional treatment was offered to
13 participants. The impact of additional sirolimus treatment
during months 12–24 is shown in Figure 2 and Table S1.
Of those in the OFF SIROLIMUS AFTER WK 52 group
(n=15) who received no additional study drug during months 12–
24, there was 1 participant with a partial response, 13 with stable
disease, and 1 with progressive disease at 24 months. In contrast,
of those in the ON SIROLIMUS AFTER WK 52 group (n=13)
who received additional treatment during months 12–24, there
were 6 with a partial response, 7 with stable disease, and 0 with
progressive disease at 24 months. The difference in the proportion
of subjects with a partial response (versus stable disease plus
progressive disease) was significant between these two treatment
groups (p=0.029, two-sided Fisher’s exact test). The duration of
sirolimus treatment in the ON SIROLIMUS AFTER WK 52
group varied because of logistic issues (delays in IRB approval for
amendment, time needed to obtain additional study drug supply,
and scheduling issues). In all cases, there was a period of time off of
sirolimus (mean time off was 24 weeks, range 4–44 weeks) prior to
restarting study drug. The average total duration of treatment
(including the first 52 weeks) was 78 weeks (range 60–100). In 2
cases, the month 24 visit was delayed (to 26 and 28 months
Figure 1. Enrollment Chart.
doi:10.1371/journal.pone.0023379.g001
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treatment during months 12–24 was 3–15 ng/ml. The dose and
frequency of drug level monitoring was at the discretion of the
treating study physician. See additional details in Table S1. On
average, tumor regrowth back to baseline was observed in the
OFF SIROLIMUS AFTER WK 52 group (n=15), but not in the
ON SIROLIMUS AFTER WK 52 group (n=13), and there was
substantial variation in individual cases. As shown in Figure 2C,D,
the percent change at 24 months (104 weeks) in the OFF
SIROLIMUS AFTER WK 52 group was 1.1%, but was 233.5%
in the ON SIROLUMUS AFTER WK 52 group ( p,0.001,
Mann-Whitney test). Consistent with this, if kidney tumor size
(sum LD) at week 104 is compared with kidney tumor size at
baseline, mean tumor size was similar in the OFF SIROLIMUS
AFTER WK 52 (p not significant for week 0 versus week 104,
Figure 2E), but significantly smaller in the ON SIROLIMUS
AFTER WK 52 group (p=0.008 for week 0 versus week 104,
paired t test, Figure 2F). Because a comparison of two groups with
different treatments from months 12–24 was not part of the
original study design, all comparative analyses were done post-hoc
and these data are considered exploratory.
Toxicity
Overall, sirolimus was reasonably well tolerated and unexpected
toxicities were not observed. Common drug related grade 1–2
events with a frequency of .20% included: stomatitis, hypertri-
glyceridemia, hypercholesterolemia, bone marrow suppression
(anemia, mild neutropenia, leucopenia), proteinuria, and joint
pain. Drug related grade 3 events were rare and included:1-
lymphopenia, 1-headache, 1-weight gain. These events did not
require intervention (headache, weight gain) or were clinically
insignificant (lymphopenia). See Table 2 for a summary of
common grade 1–2 adverse events and all grade 3 events.
Pneumonitis is a known serious toxicity of mTOR inhibitors [32]
so study staff was vigilant regarding stopping study drug promptly
if respiratory symptoms were reported. There was one case of
grade 1 drug related pneumonitis/pulmonary infiltrates observed.
See Text S1 and Table S2 for details on serious adverse events
unrelated to treatment, 4 participants with tumors unrelated to
TSC, and the complete toxicity data. See Tables S9, S10, S11,
S12 regarding kidney cysts, renal function, proteinuria and
hematuria.
Most subjects missed some doses of sirolimus during the study
for a variety of reasons. In the 28 subjects who completed 52 weeks
of treatment, study drug was held per protocol for .10 days in
seven subjects for medical reasons including: pneumonia-2,
bronchitis-1, surgery-3, edema and herpes zoster-1. Study drug
was held for .10 days for issues not specified in the protocol in
another three subjects (inadequate birth control-1, symptomatic
mouth ulcers-2). Study drug was restarted in most cases and the
week 52 visit was adjusted per protocol so missed doses were made
up at the end of year 1. Most others (,15 subjects) missed between
1 and 9 doses of study drug for minor infections or to let mouth
ulcers heal.
Regression of brain tumors and liver angiomyolipomas
There were 13 participants with a measurable SEGA (brain
tumor) at baseline ranging in size from 0.9–3.0 cm. SEGA
measurement data were available after 52 weeks of sirolimus
treatment in 11 individuals (Figure 3A–E and Figure S4). Tumor
regression was observed in 7 cases and SEGA size was stable in the
other 4 cases. The mean SEGA diameter was 1.6760.64 cm at
baseline and 1.2460.69 cm at week 52 (p=0.016, Wilcoxon
signed rank test). The mean decrease in SEGA diameter was
25.7% (this corresponds to ,59% decrease in volume assuming
the tumor is spherical). There was one dramatic example of a near
complete response in a subject who was not a surgical candidate.
Liver angiomyolipomas were present at baseline in 15 subjects
(42%) but only 5 cases had measurable disease with a longest
diameter of at least 2 cm. Best responses for percent change from
baseline diameter were 214.3%, 0.0%, 28.6%, 272.9%, and
264.8% (mean of 232.1%), see Figure 3F. Tumor regression was
observed in all cases (n=4) that completed 52 weeks on study. For
more details, see Table S3.
Skin lesions, lung function, tubers, SENs, and seizures
We collected baseline and week 52 data on facial angiofibromas,
shagreen patch, ungual fibromas, and hypomelanotic macules. At
52 weeks, clinical site investigators reported their clinical
impression on response using the following four subjective choices:
improvement, no change, worse, unable to evaluate. After one
year of sirolimus treatment, we observed subjective improvement
in facial angiofibromas, shagreen patches, ungual fibromas, and
hypomelanotic macules (Figure 3G). These observations indicated
improvement in 57% (16/28) of facial angiofibromas, 18% (5/28)
of hypomelanotic macules, 29% (8/28) of shagreen patches, 29%
(8/28) of ungual fibromas, and 21% (6/28) of forehead plaques.
See Table S5 for additional details.
The evaluation of pulmonary function before and after
sirolimus treatment was another important objective of this study
because LAM is an important cause of early mortality for women
with TSC, 10–20% of women with TSC are at risk for developing
clinically significant LAM [6,33], and up to 30% of women with
TSC have cystic lung abnormalities which are presumed to be an
early stage of LAM [7,34,35]. Pulmonary function testing was
done in 24 female participants at baseline and 18 of these had
follow-up PFTs at week 52. We observed stable lung function
(FVC, FEV1, DLCO) in those with TSC/LAM (n=15, females
with LAM), Figure 3H–J. In a subset with moderate LAM (n=5),
there was some improvement in FVC and FEV1: FVC increased
by 0.31 L (from 3.50 L to 3.81, p=0.06, Wilcoxon signed rank
test), FEV1 increased by 0.08 L (from 2.38 L to 2.46 L, p value
not significant), and DLCO was stable (13.69 ml/min/mm Hg at
baseline and 13.91 ml/min/mm Hg at week 52), see Tables S6,
S7 and Figures S5, S6, S7 for PFT findings in the subset with
LAM.
Brain manifestations were common in study participants.
Exploratory data was collected on tubers, subependymal nodules
(SENs), and seizures before and after 52 weeks of sirolimus
Figure 2. Kidney angiomyolipoma regression with sirolimus treatment. Panel A) percent change in kidney tumor size (sum LD) for
individual cases (black bars-best response during year one on study; adjacent white bars-week 52 response for same subject). All subjects were
treated with sirolimus from weeks 0 to 52. Panels B and C) percent change in kidney tumor size compared with baseline for kidney tumors at each
time point. After week 52, a subset (Panel B) was observed off treatment (black, OFF SIROLIMUS AFTER WK 52 group, n=15). Another subset (Panel C)
received additional study drug treatment after week 52 (red, ON SIROLIMUS AFTER WK 52 group, n=13). Panel D) percent change in kidney tumor
size at 24 months (104 weeks) for indicated groups. Panel E) kidney tumor size at week 0 and week 104 (month 24) for the OFF SIROLIMUS AFTER WK
52 group. Panel F) kidney tumor size at week 0 and week 104 (month 24) for ON SIROLIMUS AFTER WK 52 group.
doi:10.1371/journal.pone.0023379.g002
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or seizures (see Text S2 for details).
Serum VEGF-D levels are elevated at baseline, decrease
with sirolimus treatment, and correlate with kidney
angiomyolipoma size
Vascular endothelial growth factor (VEGF) signaling is an
important signal transduction mechanism that regulates angio-
genesis and lymphangiogenesis. There are several VEGF isoforms
(A–E) that bind dimers of VEGF receptors 1–3, which all have
intracellular tyrosine kinase domains and play a role in regulating
these important processes [36]. It is known that VEGF-D signaling
is particularly important for lymphangiogenesis [37]. Serum
VEGF-D levels have been measured in several cohorts of sporadic
LAM patients with a variety of comparison groups (summarized in
Table S4). Because of the related molecular defect in sporadic
LAM and TSC [38] and recent evidence that VEGF-D may be
involved in the pathogenesis of sporadic LAM [39,40,41,42], we
measured serum VEGF-D levels in our participants. We found
that baseline VEGF-D levels were elevated and decreased
significantly after 52 weeks of sirolimus treatment (Figure 4).
The mean baseline VEGF-D level in our study population (n=28)
was 7,827610,080 pg/ml (95% CI 3,916–11,740). At week 52,
the mean VEGF-D level was 2,21564,319 pg/ml (95% CI 540–
3,890, p,0.0001 using the Wilcoxon signed rank test). The two
subjects with an increase in VEGF-D at week 52 had stable
disease; they were both males so PFT data is not available. We
observed higher VEGF-D levels in women (9,696610,985 pg/ml)
compared with men (2,21762,546 mg/ml, p=0.026 using the
Mann-Whitney test). We also observed higher VEGF-D levels in
TSC/LAM (10,070610,946 pg/ml) compared with TSC
(2,21964,098 pg/ml, p=0.004). We looked for and did not find
a correlation between VEGF-D levels and PFTs (FVC, FEV1,
DLCO) in the subset with TSC/LAM. Although there was no
correlation between baseline PFTs (or change in PFTs) and
VEGF-D levels, we did observe a correlation between VEGF-D
levels and kidney angiomyolipoma size at baseline (Spearman
correlation coefficient 0.56. p=0.0020) and week 52 (Spearman
correlation coefficient 0.43, p=0.022), Figure 4C, D.
Discussion
The major objectives of this single arm, multicenter, phase 2
study were to evaluate kidney angiomyolipoma response to and
tolerability of sirolimus treatment. Overall, we found that sirolimus
is relatively safe and may be a useful systemic option for treating
patients with problematic multifocal kidney angiomyolipomas and
Table 2. Summary of toxicity data: all drug related grade 3 events and grade 1–2 events occurring in .10% of subjects.
ALL EVENTS INCLUDING UNRELATED
TOXICITIES TREATMENT RELATED EVENTS
All Events (36 patients) Grade 1 Grade 2 Grade 3
All Grades
(1–3) Grade 1 Grade 2 Grade 3
All Grades
(1–3) Percent*
Alkaline phosphatase 7 1 0 8 4 0 0 4 11.1%
ALT, SGPT 4 1 0 5 3 1 0 4 11.1%
Diarrhea w/o prior colostomy 10 1 0 11 3 1 0 4 11.1%
Head/headache 7 1 1 9 3 1 1 5 13.9% #
Hematologic-other 11 0 0 11 4 0 0 4 11.1%
Hemoglobin 6 2 0 8 6 2 0 8 22.2%
Hypercholesterolemia 13 3 0 16 11 3 0 14 38.9%
Hypertriglyceridemia 12 8 0 20 10 8 0 18 50.0%
Infection Gr0-2 neut, urinary tract 6 2 0 8 4 2 0 6 16.7%
Infection w/unk ANC sinus 3 2 0 5 3 2 0 5 13.9%
Infection w/unk ANC upper airway NOS 2 2 0 4 2 2 0 4 11.1%
Irregular menses 5 1 0 6 5 0 0 5 13.9%
Joint, pain 10 0 1 11 8 0 0 8 22.2%
Leukocytes 15 3 0 18 11 3 0 14 38.9%
Lymphopenia 4 0 1 5 2 0 1 3 8.3% #
Metabolic/Laboratory-other 8 0 0 8 4 0 0 4 11.1%
Necrosis, oral 15 6 0 21 15 6 0 21 58.3%
Neutrophils 10 3 0 13 6 2 0 8 22.2%
Nose, hemorrhage 6 0 0 6 5 0 0 5 13.9%
Proteinuria 12 3 0 15 7 3 0 10 27.8%
Rash: acne/acneiform 3 2 0 5 2 2 0 4 11.1%
Skin-other 5 0 0 5 4 0 0 4 11.1%
Weight gain 1 0 1 2 0 0 1 1 2.8% #
WORST DEGREE 4 24 8 36 6 26 3 35
#treatment related grade 3 event-headache, lymphopenia, weight gain.
*percent of treatment related adverse events occuring in .10% of those enrolled and/or those with a grade 3 treatment related event.
doi:10.1371/journal.pone.0023379.t002
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PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e23379Figure 4. Serum VEGF-D levels are elevated at baseline, decrease with sirolimus treatment, and correlate with kidney
angiomyolipoma size. Panel A shows baseline serum VEGF-D levels for all subjects and indicated subgroups (women, men, TSC/LAM and
TSC). According to other studies [39,41], mean serum VEGF-D levels in control female populations are 300–657 ng/ml (indicated by gray box, see
additional details in Table S4, mean VEGF-D levels in control males is not available). Panel B shows that serum VEGF-D levels decrease after 52 weeks
of sirolimus treatment. Panels C and D show the correlation between kidney tumor size (sum LD in cm) and serum VEGF-D levels (pg/ml) at baseline
(Panel C) and week 52 (Panel D).
doi:10.1371/journal.pone.0023379.g004
Figure 3. Brain tumors (SEGAs), liver angiomyolipomas, skin lesions, and lung function. Panel A shows the diameter (cm) of brain tumors
(SEGAs) at baseline and week 52 in 11 participants. T1 post gadolinium MR images (courtesy of Dr. Nathaniel D. Wycliffe, Department of Radiology,
Loma Linda University School of Medicine) in panels B–E show a SEGA near the right foramen of Monroe that measured 1.8 cm maximal diameter at
baseline (B,D) with near complete resolution of the lesion after sirolimus treatment (C,E).. Panel F is a graph of liver angiomyolipoma size for all cases
(longest diameter in cm) at baseline and at best response. Panel G shows changes in TSC skin lesions with sirolimus treatment. Panels H–J show
pulmonary function data (FVC, FEV1, DLCO) at week 0 and week 52 for female participants with TSC/LAM (n=15). See Tables S6, S7 and Figures S5,
S6, S7 for data on LAM subsets.
doi:10.1371/journal.pone.0023379.g003
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24 months in a subset treated with additional sirolimus during year
2 of the study. We also observed regression of liver angiomyoli-
pomas and SEGAs. Furthermore, serum VEGF-D levels were
elevated at baseline, decreased with sirolimus treatment, and
correlated with kidney angiomyolipoma size (for a comparison of
our VEGF-D results to several sporadic LAM studies, see Table
S4).
There are two other published kidney angiomyolipoma clinical
trial studies so we compared the kidney angiomyolipoma response
rate and toxicity data from our study (36 enrolled, 28 completed 1
year of sirolimus treatment) with the two related studies [31,43].
One is a single institution sirolimus study (25 enrolled, 20
completed 1 year of sirolimus treatment) and the other is a UK
multicenter sirolimus trial (16 enrolled, 10 completed 2 years of
sirolimus treatment). Both our study and the UK study used
RECIST criteria. We observed an overall response rate of 16/36
(44.4%) and the mean decrease in the sum LD for kidney tumors
size was 29.9% with 1 year of treatment. In the UK study, the
response rate was 8/16 (50%) with 2 years of treatment, and the
mean decrease in the sum LD for kidney tumors was 25% at the 1
year time point. The single institution study used volumetric data
to evaluate tumor regression and found that the mean reduction in
volume was 53.2% with 1 year of treatment. Since RECIST uses a
one dimensional measurement (sum LD) and volume is a three
dimensional measurement, it is important to note that a 25–29%
decrease by RECIST corresponds to a ,59–64% decrease in
volume if we assume tumors are approximately spherical. All three
studies showed that kidney tumor regression was observed in all
study subjects who completed 1 year of treatment, although in
some cases tumor regression did not meet criteria for response by
RECIST (which requires $30% decrease in sum LD). Kidney
tumor regrowth was observed at 24 months in the subset of
participants in this study who were followed off therapy after week
52 (n=15) and in most of the single institution cohort (n=18, all
of whom were followed off therapy after week 52). Kidney tumor
responses tended to persist in a subset of our study participants
who were treated with additional sirolimus from months 12 to 24
(n=13), and in all of the UK study participants who completed 24
months on study (n=10). There were also many similarities
regarding toxicity findings across all three studies. Serious drug
related events were relatively rare (3 in our study, 6 in the single
institution study, 3 in the UK study). However, mild and moderate
toxicities were common and included mouth ulcers, hyperlipide-
mia, infections, proteinuria, and diarrhea. Additionally, our SEGA
results are similar to the SEGA regression observed in a recently
published single institution study of another mTOR inhibitor
(everolimus) that showed a mean SEGA volume decrease of 49%
at 12 months and 57% at 24 months) [44].
Progressive LAM is a devastating disorder with a known defect
in the mTOR pathway [38,45]. Both published kidney angio-
myolipoma sirolimus treatment trials also collected pulmonary
data so we compared our PFT results to those studies. Looking at
the data from individual subjects, in our study we found that after
52 weeks of sirolimus treatment, FVC increased by more than 5%
in 5/15 (33%) TSC/LAM subjects (3 moderate LAM, 2 mild
LAM) and FEV1 increased by more than 5% in 4/15 (27%) TSC/
LAM subjects (2 moderate LAM, 2 mild LAM), see Tables S7, S8
and Figures S5, S6, S7. In the UK multicenter study, FVC
decreased by 76652 ml/year and FEV1 decreased by 55694 ml/
year (n=5 subjects with PFT results over 2 years). The single
institution study reported week 52 PFT data on 11 cases with
LAM (5 sporadic LAM and 6 with TSC/LAM) and noted a higher
frequency of improvement in PFTs. In that study, FVC increased
by more than 5% in 8/11 (73%) and FEV1 increased by more
than 5% in 5/11 (45%). A major limitation in all of these studies is
that the number of patients included is low, there is no untreated
control group, pulmonary function testing is effort dependent, and
there were differences in the LAM population included in the
three studies. Furthermore, it appears that the single institution
study may have included subjects with more severe lung disease as
the average FEV1 and FVC at baseline were lower in their cohort
than in ours and the UK study. Since we observed a tendency for
improvement in the more severely affected group, this could be
one explanation for the more dramatic findings in the single
institution study. More recently, a randomized phase 3 trial of
sirolimus for the treatment of LAM showed that the sirolimus
group had significant improvement in FEV1 and FVC after 1 year
of sirolimus treatment (n=46 enrolled) compared to the placebo
group (n=43 enrolled). In this phase 3 study, subjects with more
severe LAM were enrolled (FEV1 of ,70% of predicted was
required for study entry) and mean FEV1 remained stable in the
sirolimus group (change from baseline to 12 months was
19624 ml) compared with the placebo group (21346182 ml,
p=,0.001). Additionally, mean FVC showed some improvement
in the sirolimus group (976260 ml) compared with the placebo
group (21296233 ml, p=0.001) [46]. These numbers are quite
similar to our findings that in subjects with LAM (n=15), the
mean FEV1 change from baseline to week 52 was 20 ml and the
mean FVC change from baseline to week 52 was 130 ml. A
limitation of all LAM studies completed to date is that the
treatment period was relatively short (12 months) so longer term
studies are now needed. Although several studies now show
improved pulmonary function with sirolimus treatment, it is not
clear that that long term benefits will outweigh risks, especially
considering that sirolimus is an immunosuppressant and pneumo-
nitis is a known and potentially serious toxicity of mTOR
inhibitors [32,47]. Ideally the benefits and risks of using of
sirolimus for the treatment of LAM will be further evaluated in
longer term studies.
To our knowledge, this is the first clinical trial to report VEGF-
D results in a TSC population with kidney angiomyolipomas
before and after mTOR inhibitor treatment. The correlation
between VEGF-D and kidney tumor size suggests that serum
VEGF-D levels may be useful for monitoring kidney angiomyo-
lipoma size over time. Our observations that VEGF-D levels are
elevated at baseline and decrease with sirolimus treatment in a
population with kidney angiomyolipomas associated with kidney
disease are consistent with the VEGF-D results reported in the
phase 3 sirolimus trial for women with LAM reported recently
[46]. The clinical application of using VEGF-D levels to monitor
kidney angiomyolipomas or other features of TSC and/or LAM
will need confirmation in future studies. The positive results
indicate that the inclusion of VEGF-D and other biomarker
studies in future trials may yield new tools for clinical management
and contribute to the understanding of disease pathology for TSC
and/or LAM.
The numerous clinical features of TSC are well known
[6,33,48] and well represented in our study participants
(Table 1). There are significant unmet medical needs in this
population; involvement of multiple organs is common, and many
with TSC are living with chronic disabilities. The data reported
here indicate that sirolimus treatment is a promising new approach
to treatment for problematic kidney angiomyolipomas, liver
angiomyolipomas, and SEGAs. Strengths of this study include: it
is a multicenter study so is less prone to selection bias than single
institution studies, tumor response was observed in multiple organ
systems (kidney, brain, liver, skin) and this is the first TSC trial to
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angiomyolipomas. Limitations of this study include: it is a single
arm, open label study, the follow-up duration was only 2 years,
pediatric subjects were not included, and skin lesion assessment
was subjective. Future trials for TSC related tumors should include
longer duration sirolimus studies and pediatric subjects. Because
the severity of kidney angiomyolipomas and other manifestations
of TSC are variable, randomized trials that include patient
reported or quality of life outcomes will have the highest impact
regarding guiding the optimal use of mTOR inhibitors for the
treatment of TSC. There is preclinical [17] and case report data
[49] showing that lower sirolimus doses may be equally effective in
treating TSC related kidney tumors. Therefore, trials using lower
maintenance doses to see if the response is preserved while
minimizing toxicity should also be considered. Brain manifesta-
tions (seizures, cognitive impairment, and behavioral problems)
are a major source of morbidity for individuals with TSC. The
improvement in cognition and seizures with sirolimus in mouse
models [5,16,18], together with the efficacy and safety data
reported here and other TSC mTOR inhibitor trials, indicate that
clinical trials in children and adults with more severe manifesta-
tions of these features are now justified. Our skin lesion data,
together with preclinical and case report data [50,51,52] indicate
that studies evaluating systemic and/or topical sirolimus for
treating TSC skin lesions are worthwhile. Our pulmonary function
data suggest that longer term studies of pulmonary outcomes in
women with progressive and/or moderate to severe LAM are of
interest. As there are now several ongoing TSC and/or LAM trials
investigating the utility of RAD001 (a rapamycin analog, also
known as everolimus and Afinitor), it would also be useful to
pursue comparative effectiveness studies in order to directly
compare efficacy, safety, and costs of different mTOR inhibitors.
There are recent preclinical studies using mouse models of TSC
related tumors that indicate other approved drugs (such as
angiogenesis inhibitors, interferon-gamma, asparaginase) may
have potential therapeutic utility as single agents or in combina-
tion with mTOR inhibitors [15,17,53,54]. However, these studies
show that non-mTOR inhibitors appear to be less effective than
single agent mTOR inhibitors. Based on this, we suggest that
clinical investigation of non-mTOR inhibitors as single agents or
in combination with a mTOR inhibitors should be evaluated as
second line therapy for problematic TSC related tumors that are
not responding to an mTOR inhibitor. As the response of TSC
related tumors in mouse models is consistent with response of TSC
related tumors in humans, we anticipate that future preclinical
studies have significant potential to identify other promising new
medical approaches for the treatment of TSC and/or LAM.
This multicenter study should provide useful efficacy and safety
data to clinicians who are considering the option of recommending
sirolimus treatment for individuals with TSC and problematic
kidney angiomyolipomas or other TSC associated tumors.
Although there are alternative treatment options for problematic
kidney angiomyolipomas (vascular embolization, nephrectomy,
partial nephrectomy), these are all local, invasive procedures with
associated risks. Furthermore, the available local interventions are
often not suitable for the bilateral, multifocal kidney tumors that
are frequently observed associated with TSC [25]. Ultimately it
will be important to demonstrate that mTOR inhibitors can
improve longer term outcomes in TSC and/or LAM patients with
problematic kidney angiomyolipomas. Although there are chal-
lenges that slow the rate of clinical research progress for
uncommon disorders [55], the quickest path to evaluating the
benefits and risks of long term treatment is to pursue evaluation of
mTOR inhibitors in larger numbers of affected individuals in the
context of clinical studies that include substantial long term follow-
up for both efficacy and safety endpoints.
Supporting Information
Figure S1 MR images of kidney angiomyolipoma before
and after sirolimus treatment. Axial T1-weighted fat-
saturated post contrast MR images demonstrate an angiomyoli-
poma (arrow) in the upper pole of the left kidney measuring
2.81 cm maximal diameter at baseline, and 1.99 cm maximal
diameter at week 52.
(DOC)
Figure S2 MR images of kidney angiomyolipoma before
and after sirolimus treatment. Post contrast MR images
demonstrate an angiomyolipoma (arrow) in the right kidney
measuring 6.03 cm maximal diameter at baseline, and 3.91 cm
maximal diameter at week 52.
(DOC)
Figure S3 MR images of kidney angiomyolipoma before
and after sirolimus treatment. Post contrast MR images
demonstrate an angiomyolipoma (arrow) in the right kidney
measuring 3.62 cm maximal diameter at baseline, and 2.26 cm
maximal diameter at week 52.
(DOC)
Figure S4 MR images of SEGA (brain tumor) before and
after sirolimus treatment. T1 post gadolinium MR images
demonstrate a SEGA that measured 2.03 cm at baseline and
1.68 cm at week 52.
(DOC)
Figure S5 Pulmonary function: FVC before and after
sirolimus treatment in LAM subgroups.
(DOC)
Figure S6 Pulmonary function: FEV1 before and after
sirolimus treatment in LAM subgroups.
(DOC)
Figure S7 Pulmonary function: DLCO before and after
sirolimus treatment in LAM subgroups.
(DOC)
Text S1 Serious adverse events unrelated to study drug
and non-TSC related tumors.
(DOC)
Text S2 Tubers, SENs, and seizures before and after
sirolimus treatment.
(DOC)
Table S1 Complete kidney angiomyolipoma response
data.
(DOC)
Table S2 Complete toxicity data.
(DOC)
Table S3 Complete data on response of measurable
liver angiomyolipomas.
(DOC)
Table S4 Summary of serum VEGF-D levels from this
and other studies. In this table we have summarized data from
this study and all published VEGF-D data related to sporadic
LAM. When all studies are compared, there are some similar
trends. Four studies show that VEGF-D levels in sporadic LAM
are greater than those in healthy controls [39,40,41,42]. Our study
and two others [41,42] show that VEGF-D levels in TSC/LAM
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a phase 3 sirolimus LAM study [46] show that, in individuals with
TSC and/or LAM, VEGF-D levels decrease with sirolimus
treatment. One problem with comparing VEGF-D data across
different studies is that results are not reported consistently. As
shown in the table, studies have used different descriptive statistics
(mean, median, or geometric mean) to report their findings.
(DOC)
Table S5 TSC skin manifestations before and after
sirolimus treatment. These observations indicate that TSC
related skin lesions seem to improve in some individuals after 52
weeks of sirolimus treatment. It is particularly encouraging that
improvement was reported for facial angiofibromas in 57% of
participants. Although the subjective nature of the assessment is a
limitation of this data, these findings are consistent with a recent
case report on the efficacy of systemic sirolimus for the treatment
of TSC skin lesions [51]. Topical sirolimus is also of therapeutic
interest because it has anti-tumor activity in a mouse model for
TSC related tumors [52] and there is also a recent case report on
the potential utility of topical sirolimus for the treatment of TSC
skin lesions [50]. Overall, the exploratory results on TSC skin
lesions indicate that additional clinical trials evaluating systemic or
topical sirolimus for the treatment of TSC related skin disease
could lead to new therapeutic options for these problems.
(DOC)
Table S6 Complete pulmonary function data before and
after sirolimus treatment.
(DOC)
Table S7 Summary of pulmonary function before and
after sirolimus treatment in women with LAM. Of the 18
subjects with baseline and week 52 PFT data, 15 had TSC/LAM
(10-mild LAM, 5-moderate LAM), and 3 did not. For all 15 with
TSC/LAM, on average there was a 4.3% increase in FVC, 0.9%
increase in FEV1, and 0.9% decrease in DLCO when week 52
PFT results were compared with baseline data. If this group is
divided into mild and moderate LAM subgroups, those in the
moderate LAM subgroup (n=5) had more evidence for
improvement in FVC (8.9% increase) and FEV1 (3.4% increase)
at week 52. In the group with moderate LAM, FVC increased
from 3.50 to 3.81 L (p=0.06, Wilcoxon signed rank test), FEV1
increased by 0.080 L during this study (from 2.38 L to 2.46 L, p
value not significant), and DLCO was stable (13.69 ml/min/mm
Hg at baseline and 13.91 ml/min/mm Hg at week 52). This is in
contrast to epidemiology studies in which an annual decline in
FEV1 of 0.06–0.1 L and decline in DLCO of 0.6–0.9 ml/min/
mm Hg has been observed in cohorts with LAM [56,57]. FVC and
FEV1 remained close to baseline in the No LAM and Mild LAM
groups, however a 7.0% decrease in DLCO was noted in the No
LAM group at 52 weeks.
(DOC)
Table S8 TSC gene mutations. TSC gene mutation testing is
now commercially available so we collected this data in our study
subjects (see Table below). There were 18 cases that underwent
mutation testing, 15 that were not tested, and 3 for whom testing
status is unknown. In the 18 cases that were tested, 14 had TSC2
gene mutations, 0 had TSC1 mutations, and no mutation was
identified in 4 cases. The TSC2 mutation spectrum included 3
missense, 3 in frame deletions, 1 frame shift deletion, 3 nonsense, 1
splice, 1 large deletion, 1 inversion, and 1 unknown mutation type.
When we compare this data (14 TSC2 mutations, 0 TSC1
mutations, 3 with no mutations identified ) to previously published
genotype-phenotype data it appears that there may be a slightly
higher frequency of TSC2 mutations in the participants of this
study (14/18, 78%) compared with the TSC populations from two
genotype-phenotype studies where the frequency of TSC2
mutations was 66–70% [6,33]. There were a number of subjects
for whom testing was not done (15/36, 42%), which suggests that
mutaton testing is not considered critical and while mutaton
testing can be very helpful for genetic counseling purposes, the
expense may be a barrier for many, and testing is not considered
critical for management decisions in this group.
(DOC)
Table S9 Kidney cysts before and after sirolimus
treatment. There were 22/36 (61%) participants with renal
cysts at study entry. To document the severity of kidney cysts
associated with TSC, we graded these on a scale from 0 to 4 as
follows: grade 0-no cysts, grade 1-up to 2 small cysts (all ,2 cm),
grade 2-more than 2 small cysts (all ,2 cm), grade 3-more than 2
cysts with at least one .2 cm, grade 4-classic polycystic kidney
disease. In our cohort, of the 22 with kidney cysts, grade 3 was
most common (n=9), followed by grade 2 (n=6), grade 1 (n=5),
and grade 4 (n=2). At week 52 on study, renal cysts data was
available in 27 cases with the following results: grade 0 (n=11),
grade 1 (n=3), grade 2 (n=5), grade 3 (n=7), grade 4 (n=1). The
table below lists the data for the 27 cases where kidney cyst data
was available at both study entry and week 52. Although most (19
cases) had no change in kidney cyst grade with sirolimus
treatment, there were 6 with a change in kidney cyst grade at
week 52. It is interesting to note that kidney cyst grade increased in
3 cases and decreased in 3 cases. Although our data is limited
because of the small numbers, overall our findings indicate that
sirolimus treatment does not result in major changes to cystic
kidney disease associated with TSC.
(DOC)
Table S10 Kidney function before and after sirolimus
treatment. Almost all those enrolled had good renal function
with a normal creatinine and BUN at baseline. There were only 6
with a creatinine $1.5 mg/dL at study entry. The average
creatinine at study entry was 1.1060.40 mg/dL (range 0.7–2.6,
n=36). The average blood urea nitrogen (BUN) at study entry was
17.75610.70 mg/dL (range 8–70, n=36). Sirolimus was not
nephrotoxic in this population. Based on creatinine and BUN data
at study entry and week 52, there was no significant difference
after 52 weeks of drug treatment. For the 28 participants who
completed 52 weeks of treatment, the average creatinine was
1.0160.27 mg/dL at week 0 and 1.0160.33 mg/dL at week 52.
Similarly, the average BUN was 15.8265.70 mg/dL at week 0
and 15.4865.80 mg/dL at week 52 (see details in table below).
(DOC)
Table S11 Summary of proteinuria data. At study entry,
proteinuria was not common but was noted in 4 subjects (31 with
no proteinuria, 1-unknown). Of the 4 with proteinuria, according
to urine dipstick testing, there were 2 with trace to 1+ proteinuria,
1 with 2+ proteinuria, and 1 with 3+ proteinuria. We did observe
an increased frequency of proteinuria with sirolimus treatment,
but in most cases proteinuria was trace to 1+. More severe (3+)
proteinuria was less common but was observed in 2/28 (7.1%)
subjects at week 52. In one case, the 3+ proteinuria prompted a
sirolimus dose reduction and treatment with lisinopril. The data is
summarized in the table below. There were 2 cases that had no
proteinuria at baseline, but had 2+ or 3+ proteinuria at week 52.
There were also 2 cases that had 2+ to 3+ proteinuria at baseline
but had improvement at the week 104 visit. At week 52 there were
10 cases with proteinuria, at week 78 there were 6 cases with
proteinuria, and at week 104 there were 11 cases with proteinuria.
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the 11 cases with trace to 1+ proteinuria at week 104, 7 were
taking sirolimus according to the amended version of the protocol.
Our data shows that an increased frequency of mild proteinuria
may be a side effect of sirolimus treatment in this study population,
which is consistent with the known toxicities of sirolimus in the
kidney transplant population (Rapamune product information). It
is important to note that severe proteinuria was infrequent and in
2 cases proteinuria improved during sirolimus treatment.
(DOC)
Table S12 Summary of hematuria data. Hematuria was
not common, but was observed in 4 participants at study entry. In
all 4 cases, baseline hematuria was minimal (up to 20 RBCs/high
powered field (hpf)). As shown in the table below, at each time
point there were 3–4 participants with minimal to mild hematuria
(up to 10,000 RBCs/hpf). There were no cases of moderate/severe
hematuria (.10,000 RBCs/hpf) at any time during this study.
Interestingly, minimal to mild hematuria seemed to come and go
in different participants over time. There were a total of 14
subjects who had minimal to mild hematuria at one of these time
points (but not others) and 1 subject who had mild hematuria at 2
time points. Hematuria was clinically insignificant, remained
infrequent, and generally did not persist so does not appear to be
related to treatment with sirolimus.
(DOC)
Table S13 Complete list of protocol deviations/
violations.
(DOC)
Protocol S1 Trial Protocol. Original protocol v011805.
(DOC)
Protocol S2 Final protocol version v013009.
(DOC)
Checklist S1 CONSORT checklist.
(DOC)
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